Navigation Links
Physicians Eagerly Await Xarelto but Generic Price Advantage Could be a Sticking Point
Date:3/17/2010

CAMBRIDGE, Mass., March 17 /PRNewswire/ -- Sermo (http://www.sermo.com), the world's largest online community for physicians, today announced the results of a new Sermo Category Report titled "Anticoagulant Therapies: Physicians Social Media Conversations." The report analyzes a full year of peer-to-peer conversations about blood clotting, anticoagulation, anti-platelet, and thrombolytic treatments. According to the findings, although physicians highly anticipate Xarelto (Bayer/ Johnson & Johnson), they have concerns about its safety and cost. Many physicians note that generics will likely benefit from an assumed price advantage even though the potential for Xarelto is high.

"Physicians constantly need to walk a fine line, weighing the risk of stroke against the risk of bleeding," said Dr. Adam Sharp, Chief Medical Officer at Sermo.  "If Xarelto can help balance these risks through an oral, non-monitored treatment, it has a lot of potential to encourage compliance and improve patient satisfaction.  Physicians on Sermo are optimistic to see if Xarelto can deliver on this promise, but still have questions about safety and cost."

Although speculation about Xarelto makes it standout among physician discussion about anticoagulants, risk management and existing treatment options drive much of the conversation.  The report closely examines which issues are discussed most frequently, how physicians feel about brands and therapies, and changes in physician perception about treatments over time.

Top companies and medications analyzed in this report include Coumadin (Bristol-Myers Squibb), Xarelto (Bayer/Johnson & Johnson), Plavix (Bristol-Myers Squibb/sanofi-aventis), Lovenox (sanofi-aventis), Effient (Eli Lilly), Heparin, and thrombolytics.

Thrombosis is the 5th most discussed medical condition within the Sermo community.  Leveraging Sermo's social media platform, the report analyzes more than 5,000 comments generated by 1,672 physicians from 2/09-1/10.  

Visit http://www.sermo.com/client/anticoagulants or call 877-778-3963 to learn more about this report.

About Sermo Category Reports:

Everyday, physicians on Sermo have discussions that shape their practices and prescribing behavior. Sermo Category Reports tap into these peer-peer conversations to provide valuable market intelligence not possible through other channels. Reports are in PowerPoint format and include full discussion analysis. Learn more.

About Sermo

Sermo is the largest online physician community in the US, where over 112,000 practicing physicians collaborate to improve patient care. Through a unique set of social media tools, Sermo provides access to its community for organizations that need fast, actionable MD insights into treatments, drugs and devices. Visit http://www.sermo.com or call client services at 877-778-3963 to learn more.  

SOURCE Sermo

Back to top

RELATED LINKS
http://www.sermo.com

'/>"/>

SOURCE Sermo
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mayo Clinic Physicians Report Findings from Research on Sleep Disorders
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
4. Physicians Will Benefit from Medical Software Advice Website
5. Physicians Reconsider Implications of Enhance Trial
6. US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings
7. AlphaDetail AlphaPulse(TM): Most Practicing Physicians React Positively to FDA Panels Recommendation for Additional Cardiovascular Safety Trials for New Diabetes Medications.
8. Physicians Estimate That if Approved, Ceftobiprole Will Steal Nearly a Third of Zyvoxs Patient Share in the Treatment of Nosocomial Pneumonia
9. Physicians Health Study II Finds No Magic Bullet for Preventing Cardiovascular Disease
10. Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients
11. Fertility Physicians of Northern California Researchers Test New Forms of Progesterone Medication for Luteal Support During IVF
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/9/2017)... , Sept. 9, 2017  Eli Lilly and Company ... and secondary endpoint data for lasmiditan, an investigational, oral, ... demonstrated statistically significant improvements compared to placebo in the ... today at the 18th Congress of the International Headache ... "The data presented today demonstrate lasmiditan,s potential to ...
(Date:9/7/2017)... nearly two decades, New Life Agency has been committed to providing the ... Life Agency announces a powerful three-way partnership designed to deliver substantial savings ... ... http://www.schrafts2.com/ (PRNewsfoto/PharmaCareCard) ... http://pharmacarecard.com/ (PRNewsfoto/PharmaCareCard) ...
(Date:9/7/2017)... Sept. 7, 2017 NuvoAir (formerly called ... announced today a partnership with Novartis Pharma AG to distribute ... position as the leading mobile spirometry platform and Novartis, commitment ... ... ...
Breaking Medicine Technology:
(Date:9/22/2017)... ... September 22, 2017 , ... PITTSBURGH...Defibrillators ... often saves lives. However, if one isn’t accessible in certain locations, the risk ... defibrillation, I came up with this idea," said an inventor from Ridgecrest, Calif. ...
(Date:9/22/2017)... ... September 22, 2017 , ... SABRE is pleased ...  , Molli C., a graduate student from Sonora, California, who will begin her ... St. Thomas University in Miami, Florida, was selected from a pool of more ...
(Date:9/22/2017)... ... September 22, 2017 , ... ... rooms is celebrating the one year anniversary of its Houston-Fallbrook facility. , ... Dr. Otinwa, Facility Medical Director of First Choice Emergency Room Houston-Fallbrook. “It has ...
(Date:9/22/2017)... CA (PRWEB) , ... September 22, 2017 , ... ... groceries, wearable, and more products at customers’ doorstep. According to Smart Mart, customers ... Mart has stated to offer wearable, and customers can find clothing at discounted ...
(Date:9/21/2017)... ... September 21, 2017 , ... Process Capability ... p.m. – 3:00 p.m. ET, http://www.fdanews.com/processcapabilityindices      , Quality ... run afoul of The Quality System Regulation (§820.250), and Devicemakers find themselves staring ...
Breaking Medicine News(10 mins):